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Abstract Oral ulcers are the most common mucosal sign
in juvenile-onset systemic lupus erythematosus (JSLE).
The ulcers are one of the key clinical features; however, the
terminology of oral ulcers, especially in JSLE patients, is
often vague and ill-defined. In fact, there are several clin-
ical manifestations of oral ulcers in JSLE, and some lesions
occur when the disease is active, indicating that early
management of the disease should be started. Oral ulcers
are classified as lupus erythematosus (LE) specific, where
the lesional biopsy shows a unique pattern of mucosal
change in LE, and LE nonspecific, where the ulcers and
their histopathological findings can be found in other oral
diseases. Here, the clinical manifestations, diagnosis and
management of oral ulcers in JSLE patients are reviewed.
Key Points
Oral ulcers are one of the key clinical features in
juvenile-onset systemic lupus erythematosus (JSLE)
patients; however, the terminology remains unclear.
There are several oral ulcers in JSLE patients that
sometimes go unnoticed, and some ulcers indicate
that treatment should be started promptly.
Lesional biopsy is required when other oral diseases
cannot be excluded, such as oral lichen planus and
oral lichenoid contact lesions.
1 Introduction
Juvenile-onset systemic lupus erythematosus (JSLE) is one
of the most common autoimmune diseases in children and
has a clinical course ranging from mild, gradual onset to
rapid, progressive multi-organ failure [1]. Approximately
20% of systemic lupus erythematosus (SLE) patients are
diagnosed in childhood and adolescence, with a median age
of 11–12 years [2–5]. The prevalence of JSLE is high in
Asian and African populations, with a female predomi-
nance (female to male ratio: 4.7:1–6.2:1) [6, 7]. JSLE
patients usually present with mucocutaneous lesions, renal
involvement, central nervous system (CNS) disorders and
hematological abnormalities [4]. The diagnosis of JSLE
typically needs four out of 11 criteria based on the revised
classification criteria of the American College of
Rheumatology (ACR) 1997. However, the new Systemic
Lupus International Collaborating Clinics (SLICC) group
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classification criteria are now widely used in JSLE, and the
diagnosis requires at least four out of 17 criteria (including
at least one clinical criterion and one immunological cri-
terion), or lupus nephritis with a presence of antinuclear
antibody (ANA) or anti-double-stranded DNA (anti-ds
DNA) antibodies [8, 9].
Mucocutaneous manifestations are common signs and
symptoms in JSLE at diagnosis, and they are found in
approximately 70–75% of JSLE populations worldwide
[7, 10–14]. According to the ACR revised criteria, four
mucocutaneous features are included, one of which is oral
ulcers. The terminology of oral ulcers in these criteria is
usually ‘‘painless oral or nasopharyngeal ulceration
observed by a physician’’, yet these may be unclear,
especially in children [15]. In the new SLICC group clas-
sification criteria, oral ulcers remain included. They are
defined more specifically as oral ulcers at palate, buccal
mucosa or tongue without other causes (e.g., vasculitis or
infection) [8]. In fact, there are several types of oral ulcers
presented in JSLE patients. Moreover, some ulcers (e.g.,
palatal erythematous ulcers and aphthous ulcers) occur
particularly when disease is active. However, other types of
ulcers may appear without being related to disease activity
and severity [16, 17].
The mucocutaneous manifestations in JSLE are classi-
fied as lupus erythematosus (LE)-specific and LE-non-
specific skin diseases, according to the Gilliam
classification of skin lesions associated with LE [18].
Typical oral ulcers in the ACR criteria and SLICC group
classification criteria are LE-specific and most lesions are
categorized in chronic cutaneous lupus erythematosus
(CCLE), such as oral discoid lupus erythematosus (DLE),
whilst others are LE-nonspecific (e.g., aphthous ulcers)
[10].
We searched for literature reviews and studies in the
PubMed database using the following key words:
‘‘oral/mucosa/mucosal/mucocutaneous’’ and ‘‘lupus/LE/
SLE’’ and ‘‘juvenile/child/childhood/children’’ (until
August 1, 2016). All published articles related to the
clinical manifestations of oral ulcers in JSLE patients were
reviewed.
2 Epidemiology
Oral ulcers are the second most common mucocutaneous
manifestation in JSLE patients after butterfly rash [11], and
they are the most common mucosal sign of JSLE [19]. The
incidence of oral ulcers in JSLE is approximately
11.4–37%, which is significantly higher than in adult SLE
[4, 5, 20]. In adult patients, males have a lower rate of oral
ulcers than females, but there are no reports of gender
preference in children [21]. The common oral ulcers in
JSLE patients are palatal erythematous ulcers, oral DLE
and aphthous ulcers [10, 11].
3 Clinical Manifestations
Oral mucosa is normally characterized into three types:
lining; masticatory and specialized mucosa [22, 23]. The
lining mucosa is nonkeratinized epithelium covering buc-
cal mucosa, labial mucosa, alveolar mucosa, soft palate,
ventral tongue and the floor of the mouth [24], whereas the
masticatory mucosa is keratinized mucosa covering gin-
giva, attached gingiva and hard palate. The dorsal surface
of the tongue is covered with specialized mucosa that
consists of taste buds and epithelially derived structures
called papillae [22–24]. Understanding of these different
types of oral mucosa is important for making a diagnosis,
as some lesions tend to affect one type of tissue more than
the others. The clinical manifestations of oral ulcers in
JSLE patients are summarized in Table 1 [16, 25–30].
3.1 Lupus Erythematosus (LE)-Specific Oral Ulcers
3.1.1 Palatal Erythematous Ulcers
A palatal erythematous ulcer is the typical oral ulcer in the
ACR criteria, and it is described as a usually painless,
single/multiple lesion(s) at masticatory or keratinized
mucosa, especially the hard palate (Fig. 1a). It is an acute
sign occurring when disease is active, and sometimes is the
first clue of JSLE without skin lesions [26]. The early
lesion may be hemorrhaging before developing into the
ulcer [10]. If the ulcers are coalesced into a large erythe-
matous patch at the hard palate and extend to the soft
palate, the early onset of oral DLE should be considered.
Palatal erythematous ulcers are sometimes characterized as
acute cutaneous lupus erythematosus (ACLE) of LE-
specific skin disease in some reports [16].
3.1.2 Oral Discoid Lupus Erythematosus
Oral DLE is a well-defined, atrophic plaque with white
radiating keratotic striae and telangiectasia at lining
mucosa, especially buccal mucosa and the soft palate
(Fig. 1b) [16, 26]. JSLE patients often develop an erythe-
matous lesion with painful telangiectasia, and keratotic
scaling occurs afterward. The lesion eventually transforms
into an atrophic lesion with keratotic border [31]. The
typical oral DLE is composed of (a) white papule/plaque,
(b) central erythema, (c) a border zone of irradiating white
striae and (d) peripheral telangiectasia [27, 28]. Although
the lesion appears at lining mucosa, the masticatory
mucosa may be involved without radiating striae (e.g., hard
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palate) [28]. The dental alveolar process is another location
that should be carefully inspected, as oral DLE is easily
overlooked. Of note, the radiating white striae sometimes
resemble the Wickham striae of oral lichen planus (OLP);
therefore, a lesional biopsy should be performed if a defi-
nite diagnosis is required. Other locations of oral DLE are
not common, such as vermilion borders of buccal lips and
specialized mucosa (tongue) [10, 31].
3.1.3 Honeycomb Plaques
A honeycomb plaque is described as a chronic, well-cir-
cumscribed plaque with white lacy hyperkeratosis and
buccal erythema [16, 25, 32]. The lesion usually occurs at
both lining and masticatory tissues, but the lesion at the
lining part (e.g., soft palate) is less hyperkeratotic [25].
Some reports suggest that this lesion is a morphological
variant or a late stage of oral DLE [18]. The incidence of
honeycomb plaque in JSLE is very rare.
3.1.4 Verrucous LE
Verrucous LE is a rare type of CCLE-specific oral ulcer
that has been reported in adult SLE and JSLE [16, 33–35].
The lesion is a raised, intense keratotic plaque normally
found at lining mucosa, such as the buccal mucosa and lips.
However, the hard palate (e.g., alveolar ridge) may be
involved (Fig. 1c) [33].
3.2 LE-Nonspecific Oral Ulcers
3.2.1 Aphthous Ulcers
An aphthous ulcer is described as a white to yellow painful
ulcer with a surrounding red rim. The lesion is usually
presented with multiple lesions or in a group, and tends to
involve primarily lining tissue: the soft palate, buccal and
labial mucosa. Aphthous ulcers are more common in JSLE
patients than in adult SLE and usually occur when disease
is active [36]. There are four types of aphthous ulcer,
classified as (a) minor ulcers, smaller than 1 cm, usually
healing without scar; (b) major ulcers, larger than 1 cm,
often healing with scar; (c) herpetiform ulcers, a group of
small ulcers (more than ten lesions); and (d) severe ulcers,
a continuous minor ulcer lasting months [37]. In our
observations, the most common type of aphthous ulcer in
JSLE patients is multiple minor ulcers and less than ten
lesions (Fig. 1d).
3.2.2 Lupus Cheilitis
Lupus cheilitis is an inflammation of the buccal lips. The
typical lesion is small or diffuse, erythematous and ede-
matous, and may turn into crusty painful ulcers [29].
Cheilitis often involves the vermilion zone of the lower lip
(typical lupus cheilitis) [30]. As the lesion is found in the
sun-exposed area, lupus cheilitis is usually associated with
photosensitivity in JSLE patients [25]. Extensive erosive
lupus cheilitis that involves both upper and lower lips has
also been reported in JSLE patients and appears in active
disease (Fig. 1e) [38].
3.2.3 Other LE-Nonspecific Oral Lesions
Bullous SLE is a rare clinical manifestation developed by
circulating antibodies against type VII collagen at the sub-
epidermis. It typically presents with multiple tense bullae
at the face, neck and trunk [39]. Bullous LE at buccal
mucosa has been reported in adult SLE and JSLE patients
[40, 41].
Table 1 Clinical manifestations of oral ulcers in juvenile-onset systemic lupus erythematosus (JSLE) [16, 25]
Classification Type of lesions Locations Key clinical features
LE-specific oral
ulcers
Palatal
erythematous
ulcer
Masticatory mucosa (especially hard
palate)
Painless, single/multiple erythematous ulcer(s)
Oral discoid LE Lining mucosa (especially buccal mucosa
and soft palate)
Atrophic plaque with white radiating keratotic striae and
painful telangiectasia
Honeycomb
plaque
Lining and masticatory mucosa Chronic, well-circumscribed erythematous plaque with
white lacy hyperkeratosis
Verrucous LE Lining mucosa Raised, intense keratotic plaque
LE-nonspecific
oral ulcers
Aphthous ulcer Lining mucosa White to yellow painful ulcer(s) with erythematous halo
Lupus cheilitis Buccal lips (especially lower lip) Small or diffuse erythematous and edematous lips, or
crusty painful ulcer(s)
LE lupus erythematosus
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4 Diagnosis
Clinical evaluation and follow-up is usually sufficient for
making a diagnosis of oral ulcers. However, atypical ulcers
are sometimes difficult to diagnose, particularly when the
patients cannot fulfill the ACR criteria or the new SLICC
group classification criteria. In these circumstances,
histopathology and immunofluorescence studies are help-
ful. The histopathology of LE-specific oral ulcers (DLE)
shows hyperkeratosis with keratotic plugs. The rete ridge
of the mucosa becomes atrophic with deep dermal
inflammatory cell infiltration and edematous lamina pro-
pria. Positive periodic acid-Schiff staining is found at the
juxta-epithelial site in a thick continuous or a patchy pat-
tern [42–44]. In contrast, the histopathology of LE-non-
specific oral ulcers is varied, and no such specific pattern
can be identified, as similar findings are also seen in other
oral diseases. Direct immunofluorescence of LE-specific
oral ulcers shows a band-like deposition of immunoglob-
ulin (IgG, IgM or IgA) at the basement membrane of the
lesion [45, 46], in contrast to pemphigoid diseases, where
linear deposits can be seen [47].
Fig. 1 Oral ulcers in JSLE
patients and their differential
diagnoses. a–c LE-specific oral
ulcers: a a palatal erythematous
ulcer at hard palate; b a painful
oral discoid LE with well-
demarcated radiating white
striae at left buccal mucosa;
c verrucous LE at alveolar
ridge. d–e LE-nonspecific oral
ulcers: d multiple aphthous
ulcers with erythematous halo at
soft palate; e extensive erosive
lupus cheilitis at both upper and
lower lips. f–h The differential
diagnoses: f an oral lichen
planus with typical white
reticular striae (Wickham striae)
at left buccal mucosa and
retromolar trigone; g an oral
lichenoid contact lesion
associated with large amalgam
filling at left maxillary first
molar (arrow); h clinical
improvement 2 weeks after
replacement with non-metal
restoration. JSLE juvenile-onset
systemic lupus erythematosus,
LE lupus erythematosus
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Although clinical features are sufficient for making a
diagnosis, there are several diseases with appearances that
are similar to the oral ulcers seen in JSLE.
4.1 Oral Lichen Planus
As mentioned previously, atypical oral DLE may mimic
OLP. OLP has multiple clinical appearances, such as
reticular, erythematous, plaque-like and erosive types. Oral
DLE may resemble the reticular and erythematous types of
OLP, which can present as a white lacy patch and ery-
thematous mucosa. However, the most frequent site of
involvement in OLP is posterior buccal mucosa (rarely at
the palates) (Fig. 1f) [25, 48, 49]. Wickham striae are
characteristic of OLP, but a lesional biopsy is sometimes
necessary when a definite diagnosis cannot be made. The
histopathology shows basal cell degeneration damage and
dense subepithelial band-like infiltration of T lymphocytes
in the subjacent connective tissue [50]. Direct
immunofluorescence is also helpful, as OLP shows positive
staining with anti-fibrinogen in the dermoepidermal junc-
tion and positive staining with immunoreactive proteins in
the colloid bodies [16, 51, 52].
4.2 Oral Lichenoid Contact Lesions
An oral lichenoid contact lesion (OLCL) is a white patch or
plague at the buccal mucosa, and its appearance is similar
to oral DLE and OLP [27, 53] (Fig. 1g, h). The cause of
OLCLs is thought to be a delayed-typed hypersensitivity
reaction to a component of dental restorative materials, and
use of metallic dental fillings can induce this lesion.
OLCLs usually disappear when the metallic dental fillings
have been removed [27, 53].
4.3 Leukoplakia
Leukoplakia is a homogenous or non-homogenous white
plague at the buccal mucosa [54]. As there are no specific
histological findings in this lesion, other causes need to be
excluded [55]. Oral DLE sometimes transforms into a
white homogenous plaque when the lesion has persisted for
several months. Therefore, it should be considered as one
of the differential diagnoses in leukoplakia [56].
4.4 Herpetic Gingivostomatitis
The typical lesion comprises a group of multiple painful
vesicles on an erythematous base at the buccal lips, oral
mucosa or tongue, with red and swollen gingiva. A group
of multiple ulcers and aphthous ulcers in JSLE are quite
similar. However, the important clues of herpetic gin-
givostomatitis are prodromal symptoms and a history of
herpes simplex virus (HSV) infection. A Tzanck smear,
demonstrating cytopathic effects of the virus, is useful for
diagnosis. The lesion usually spontaneously resolves
within 2 weeks [57]. Therefore, oral ulcers in JSLE should
be considered if this lesion still persists beyond 2 weeks.
5 Management
Topical anti-inflammatory agents are the treatment of choice
for oral ulcers in JSLE [58, 59]. Topical corticosteroids (e.g.,
0.1% triamcinolone oral paste) are one of the most com-
monly used medications in JSLE patients, and shorten the
course and severity of the ulcers. The duration of corticos-
teroid usage depends on the severity of the symptoms. If the
oral lesions are refractory to the treatment, then more potent
(e.g., betamethasone or clobetasol in oral preparation) or
systemic drugs may be needed [58]. However, some oral
ulcers are very difficult to treat even when high-potency
topical corticosteroid is applied, especially palatal erythe-
matous ulcers and oral DLE [26]. Steroid-sparing agents,
such as calcineurin inhibitors (e.g., 0.03 or 0.1% tacrolimus)
are also applicable when the side effects of corticosteroids
are of concern [60, 61]. The other route of corticosteroid
administration, intra-lesional injection, is rarely used, espe-
cially in children, due to pain. Noticeably, systemic corti-
costeroids are normally prescribed as a first-line drug for
treatment in JSLE because most patients develop multiple-
organ involvement and these drugs dramatically improve the
clinical signs and symptoms, including oral ulcers [25, 62].
Antimalarial drugs, such as hydroxychloroquine, are
usually used as first-line drugs combined with systemic
corticosteroids if the patient needs systemic therapy.
However, these drugs can be used as a monotherapy in
mild cases of JSLE with mucocutaneous manifestations
(e.g., malar rash, discoid rash, photosensitivity, including
oral ulcers) [63, 64]. Complete blood counts, eye exami-
nation and liver function tests should be monitored, as drug
toxicities may occur in children.
Avoiding sun exposure, especially in patients with lupus
cheilitis and oral DLE at buccal lips, is recommended, as
UV light is an aggravating factor [18, 25]. Routine wet
dressing can soothe the pain, and keeping chapped lips
moist using petrolatum ointment or lip balm (with UV
protection) is needed.
A regular dental check-up is also recommended in JSLE
patients who present with oral ulcers. Good oral hygiene
and prevention of secondary bacterial infection with oral
rinses containing chlorhexidine should be advised [58, 59].
An infection should be suspected when the oral ulcers
become painful or bleed. Local antibiotics and antifungal
agents (e.g., nystatin) should be considered if infection is
suspected.
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6 Summary
Oral ulcers are commonly found in JSLE patients, and the
typical lesion is a painless palatal erythematous ulcer at
masticatory or keratinized mucosa, especially the hard
palate. However, most ulcers including oral DLE and
aphthous ulcers in JSLE patients appear at the lining tissue
of the oral cavity (e.g., buccal mucosa, soft palate and
tongue) and sometimes are unnoticed. Therefore, under-
standing of their clinical features and locations is very
important. Clinical evaluation and follow-up is normally
sufficient for making a diagnosis; however, lesional biopsy
is needed particularly when other diseases (such as OLP or
OLCL) cannot be ruled out. Topical corticosteroids remain
the first-line treatment of oral ulcers, but the steroid-sparing
agents (calcineurin inhibitors) can also be used in JSLE
patients.
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